From: Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
 | mucinous | p | neuroendocrine | p | poor-differentiated | p | reference | total |
---|---|---|---|---|---|---|---|---|
EGFR | 18.8% (12/64) | *** | 20.0% (8/40) | *** | 48.1% (106/220) | Â | 52.4% (418/798) | 48.5% (544/1122) |
ALK fusion | 17.1% (11/64) | *** | 0% (0/40) | - | 7.2% (16/220) | Â | 1.3% (10/798) | 3.3% (37/1122) |
KRAS | 29.7% (19/64) | *** | 5.0% (2/40) | Â | 13.2% (29/220) | * | 3.0% (24/798) | 6.6% (74/1122) |
ROS1 fusion | 0% (0/64) | - | 0% (0/40) | - | 2.7% (6/220) | Â | 0.2% (2/798) | 0.7% (8/1122) |
RET | 0% (0/64) | - | 0% (0/40) | - | 2.7% (6/220) | Â | 0.8% (6/798) | 1.1% (12/1122) |
MET | 1.6% (1/64) | Â | 0% (0/40) | Â | 4.6% (10/220) | Â | 2.9% (23/798) | 3.0% (34/1122) |